Compare Crispr Therapeutics AG (CRSP) vs 3M Company (MMM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs 3M Company — how do they compare? Crispr Therapeutics AG trades at $50.91 (market cap $4.97B), while 3M Company trades at $156.2 (market cap $81.67B). The key difference: 3M Company is far larger — about 16.4× Crispr Therapeutics AG's market cap, and 3M Company pays a 1.99% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.
| CRSP | MMM | |
|---|---|---|
Market Cap | $4.97B | $81.67B |
Sector | Health | Industrials |
52-Week High | $76.78 | $174.61 |
52-Week Low | $44.34 | $141.10 |
Enterprise Value | $3.32B | $90.07B |
Dividend Yield | — | 1.99% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRSP trades at $50.63, down 5.1% over 24 hours, amid a bearish technical signal. The company shows deep losses with a net income margin of -56,853.4% in 2025 and negative cash flow from operations. However, analyst consensus remains optimistic with a $74.50 price target, and recent news highlights FDA approval for Casgevy, expanding its gene therapy market.
The outlook hinges on commercial execution of Casgevy and pipeline progress, offering high growth potential in gene editing. Key risks include sustained cash burn, competitive pressures, and regulatory hurdles. Despite current financial challenges, strong analyst buy ratings suggest confidence in long-term value.
3M (MMM) trades at $157.70, showing minimal daily movement with a 0.11% gain. The stock faces technical headwinds with bearish moving averages but maintains strong profitability metrics including a 72.14% ROE and consistent earnings beats. Recent developments include new product launches and strategic partnerships, though the company navigates consumer segment weakness and mixed analyst sentiment.
The outlook remains balanced with solid fundamentals supporting long-term value, but near-term risks include competitive pressures and macroeconomic sensitivity. Analyst consensus suggests cautious optimism with a $143 price target, while technical indicators signal potential consolidation around current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About 3M Company
3M Company conducts operations in electronics, telecommunications, industrial, consumer and office, health care, safety, and other markets. The Company businesses share technologies, manufacturing operations, marketing channels, and other resources. 3M serves customers worldwide.
Read more on MMM →
